|Awarded On||May 20, 2015|
|Title||Wireless neuromodulation treatment for bladder dysfunction secondary to cancer|
|Program||Product Development Research|
|Award Mechanism||New Company Product Development Award|
|Institution/Organization||Nexeon MedSystems, Inc|
|Principal Investigator/Program Director||Navid Khodaparast|
|Cancer Sites||Cervix Uteri, Prostate|
Surgical resection and radiotherapy are used frequently in the treatment of prostate, cervical, and rectal cancers. While they can be life-saving therapies, these procedures often burden cancer survivors with secondary conditions such as overactive bladder (OAB). For some cancer patients and survivors, OAB symptoms are an understood outcome of life-saving cancer therapy, while others may view the risk of urinary dysfunction as a reason to forego or substitute potentially inferior forms of treatment. There is a pressing need for treating OAB in cancer patients and survivors; however, existing treatment protocols may not be suitable for patients developing symptoms secondary to cancer or treatm...